Epitomee Medical
Drug-free Capsules for Diabetes Prevention and Weight Loss
Company Overview
Snapshot
Founded in August 2005 by Dr. Shimon Eckhouse, Epitomee Medical operates with 11–50 employees. The company has raised $77 million across 4 funding rounds from 6 investors. Epitomee Medical went public on the TASE in December 2021, achieving a valuation of $203 million.
Business overview
Epitomee Medical is a public company focused on developing and commercializing ingestible therapeutic devices to address prevalent chronic diseases. Its core technology utilizes self-expanding hydro-gel scaffolds, folded into standard pharmaceutical capsules, made from biocompatible excipients and food additives. These hydro-gel scaffolds can be engineered to activate at specific pH levels, enabling targeted delivery for optimal therapeutic effects. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving both healthcare industries and consumers globally.
Strategic signal
In September 2024, Epitomee Medical announced FDA clearance for its capsule weight management device. This regulatory approval is a significant validation of the company's technology and opens a critical market pathway in the United States, signaling strong commercial potential and de-risking for investors in the competitive weight management and medical device sectors.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent regulatory achievement for Epitomee Medical?
- In September 2024, Epitomee Medical announced that the United States Food and Drug Administration (FDA) officially cleared its Epitomee® capsule weight management device.
- When did Epitomee Medical complete its pivotal clinical trial for its weight loss capsule?
- Epitomee Medical announced the successful completion of its pivotal clinical trial for the innovative weight loss capsule in January 2024.
- What was the outcome of the RESET Study for Epitomee's drug-free capsule?
- In November 2024, results from Epitomee's RESET Study were presented at ObesityWeek® 2024, demonstrating that the company's drug-free capsule helps patients shed pounds.
- When did Epitomee Medical go public?
- Epitomee Medical went public on the TASE in December 2021, with an initial valuation of $203 million.
- What was a key strategic partnership for Epitomee Medical regarding its weight loss capsule?
- In August 2020, Epitomee Medical Ltd. and Nestlé Health Science announced a partnership for the development and commercialization of the Epitomee weight loss capsule.